July 2026: Over Half of Americans Now Live in States Where Recreational Cannabis Is Legal
The legal landscape surrounding cannabis in the United States continues to evolve rapidly, transforming a once-uniform federal prohibition into a complex patchwork of state regulations. As legislative sessions and voter initiatives advance, a major demographic milestone has been cemented: more than half of the U.S. population now lives in states where the recreational use of cannabis is legally allowed.
Currently, the 50 states are divided into four distinct legal categories:
1. Recreational & Medical (24 States): Nearly half of the country has fully embraced legalization. In these 24 states (plus Washington, D.C.), adults aged 21 and older can legally purchase and possess cannabis for recreational use, alongside robust medical programs.
2. Medical Only (17 States): A total of 17 states allow comprehensive access to cannabis strictly for patients with qualifying medical conditions.
3. Low THC / CBD (8 States): Eight states maintain highly restrictive frameworks, prohibiting traditional medical marijuana but allowing limited access to low-THC cannabis oils or CBD products for specific medical needs.
4. Illegal (1 State): Idaho stands alone as the only state in the entire nation where no type of cannabis use is legally permitted under any framework, maintaining a total prohibition on both recreational and medical usage.
While federal rescheduling efforts remain under review, several states are navigating key legislative hurdles, active ballot campaigns, and policy reform. The table below details the immediate outlook for states working to establish medical access or advance toward full adult-use legalization:
| State | Status | Next Steps & Legislative Outlook |
| Idaho | Illegal | As the nation’s sole total-prohibition state, voter advocacy groups are gathering signatures for the Idaho Medical Cannabis Act ballot measure, while state lawmakers attempt to raise thresholds for citizen initiatives. |
| Kansas | Low THC / CBD | Medical legalization measures (such as SB 135) have repeatedly gained traction in legislative committees; lawmakers are working on compromise language to establish a tightly regulated, non-smokable medical program. |
| Wyoming | Low THC / CBD | Advocacy groups continue working to collect the required signatures for a statewide ballot initiative to establish a medical program, navigating steep legislative resistance. |
| Indiana | Low THC / CBD | Medical cannabis and decriminalization bills are introduced annually, though legislative leadership has largely delayed passage, pointing toward federal rescheduling before taking state-level action. |
| Georgia | Low THC / CBD | Georgia continues expanding its regulated Low-THC Oil Registry (up to 5% THC); legislative committees are working to expand qualifying conditions and streamline dispensary distribution channels. |
| Tennessee | Low THC / CBD | Lawmakers routinely evaluate medical cannabis study commissions and low-THC expansion bills, though full medical legalization faces strong committee roadblocks. |
| South Carolina | Low THC / CBD | The South Carolina Compassionate Care Act (S. 423) remains a priority measure in the legislature, aiming to permit non-smokable medical cannabis for patients with debilitating conditions. |
| North Carolina | Low THC / CBD | The North Carolina Compassionate Care Act (S3) has consistently passed the state Senate; advocates are focusing on building consensus in the House to enact a comprehensive medical program. |
| Wisconsin | Low THC / CBD | Bipartisan and conservative-backed medical cannabis proposals (e.g., SB 534 / AB 1040) continue to be debated, with lawmakers negotiating over state-managed distribution models and qualifying medical conditions. |
| Pennsylvania | Medical Only | Widely viewed as one of the top candidates for recreational expansion. Lawmakers continue to debate adult-use legalization bills (such as SB 75 and HB 758) to transition to a regulated commercial market. |
| Florida | Medical Only | Following recent setbacks in attempts to clear additional legal usage pathways, advocates are regrouping to map out future constitutional amendments to bring adult-use to the ballot. |
| New Hampshire | Medical Only | After a legalization bill (HB 186) passed the House but stalled before achieving full enactment, lawmakers are refining legislative language to build the necessary Senate consensus for a regulated market. |
July 2026: Senate Democrats Reintroduce Bill to End Federal Marijuana Prohibition and Establish Regulatory Framework
Senate Democrats have launched a renewed legislative push to end the federal prohibition of marijuana, reintroducing a comprehensive reform bill aimed at de-scheduling the drug and establishing a federal regulatory framework. Reintroduced on July 16, 2026, the Cannabis Administration and Opportunity Act (CAOA) represents the most ambitious legislative attempt to date to align federal law with the rapidly evolving landscape of state-level cannabis legalization.
The legislation, sponsored by senior Democratic senators, aims to completely remove marijuana from the federal Controlled Substances Act. Under current federal law, cannabis remains classified as a Schedule I substance – a category reserved for drugs deemed to have no accepted medical use and a high potential for abuse. By de-scheduling cannabis, the bill would formally yield to state-level policies, allowing individual states to determine their own cannabis laws without the threat of federal interference.
In addition to federal decriminalization, the comprehensive bill outlines several major reforms:
– Federal Regulation: Establishing a joint regulatory framework overseen by federal agencies to govern the production, taxation, and sale of cannabis.
– Criminal Justice Reform: Implementing measures to facilitate the expungement and resentencing of individuals with past non-violent, cannabis-related federal convictions.
– Economic and Scientific Opportunity: Encouraging federal research into the health impacts of cannabis, resolving long-standing banking hurdles for state-legal businesses, and funding programs to promote economic equity in the emerging industry.
Currently, nearly every U.S. state has legalized medical cannabis in some capacity, while 24 states and multiple U.S. territories have fully regulated recreational markets. The reintroduction of the bill comes amidst parallel administrative efforts to reform cannabis scheduling. In April, the Acting Attorney General ordered the immediate rescheduling of state-licensed medical cannabis products and FDA-approved cannabinoid drugs to the less restrictive Schedule III.
However, that executive action is currently facing legal challenges. Meanwhile, a Drug Enforcement Administration (DEA) hearing focused on a broader proposal to move all cannabis products to Schedule III concluded on July 15, though a formal judicial recommendation has not yet been issued. While a shift to Schedule III would ease tax burdens and banking restrictions for cannabis businesses, it would not legalize or de-schedule the drug federally – leaving a conflict between state and federal laws that Senate Democrats argue can only be permanently resolved through comprehensive legislation like the CAOA.
Despite the momentum of state-level legalization and public support, political analysts widely agree that the success rate for this renewed legislative push remains very low in the current Congress. Because Republicans hold a 53-45-2 majority in the Senate, the bill faces an uphill battle from the start, as GOP leadership controls which bills even make it to the floor for a vote.
Even if the bill were to be brought forward, clearing the Senate’s 60-vote filibuster threshold would require substantial, bipartisan support. Historically, Republican lawmakers have remained deeply divided on federal cannabis reform. While some libertarian-leaning Republicans support states’ rights to self-govern, the majority of the Republican caucus opposes outright federal legalization and de-scheduling due to concerns over public health, traffic safety, and drug abuse.
Without a significant shift in Republican support or a major partisan realignment in Congress, the CAOA is highly unlikely to pass in its current, comprehensive form. Instead, the bill is anticipated to serve primarily as a messaging tool ahead of the upcoming midterm elections, signaling the Democratic Party’s platform to progressive voters while laying the groundwork for smaller, incremental bipartisan compromises – such as cannabis banking reform – further down the road.
June 2026: Massachusetts Facing Potential Landmark Vote to Repeal Marijuana Legalization
Activists in Massachusetts have gathered enough petition signatures to likely force a referendum on this November’s ballot to repeal the state’s 2016 recreational marijuana legalization law. Led by the Coalition for a Healthy Massachusetts, the anti-cannabis movement cites concerns over increased product potency, public safety on roads, aggressive commercialization, and youth consumption. If successful, Massachusetts would become the first U.S. state to overturn marijuana legalization. The local cannabis industry has formed a counter-campaign called “Stop the Repeal,” warning against the destruction of businesses and the loss of significant tax revenue for the state. While early polls showed heavy opposition to a repeal, recent data indicates the race is tightening ahead of official ballot certification in July.
June 2026: Virginia Moves to Legalize Recreational Marijuana as Lawmakers Reach Deal
Virginia lawmakers have sent a new recreational cannabis legalization bill to the Governor as part of the state’s budget package, reviving efforts to establish a regulated adult-use marijuana market after years of political deadlock. The legislation would create a legal retail market for recreational cannabis, with licensed sales scheduled to begin on January 1, 2027. Virginia legalized adult possession and home cultivation in 2021, but retail sales have never been implemented due to disagreements over taxation, regulation, and the rollout timeline.
Under the proposed framework, adults aged 21 and older would be allowed to purchase up to 2.5 ounces of cannabis per transaction, an increase from earlier proposals. The measure also establishes a tax structure consisting of a 6% excise tax, a 5.3% state sales tax, and an optional local tax of up to 3.5%.
Supporters say the legislation would help transition consumers from the illicit market to a regulated system while generating revenue for the state and local governments. The delayed launch date is intended to provide regulators with sufficient time to establish licensing, compliance, and enforcement systems. The bill now awaits the Governor’s decision. The governor has previously vetoed legislation to establish a recreational cannabis retail market, leaving uncertainty over whether he will approve the latest proposal despite its inclusion in the budget agreement.
June 2026: House Democrats Press IRS for Cannabis Tax Guidance After Rescheduling Changes
A group of House Democrats is urging the IRS and Treasury Department to issue prompt guidance on how federal tax rules will apply to state-legal cannabis businesses following the federal rescheduling of certain marijuana products. The lawmakers argue that businesses need clarity on whether they can now access tax deductions and credits that were previously prohibited under Section 280E of the Internal Revenue Code.
The request follows an April 2026 decision by the U.S. Department of Justice and DEA to move FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. Because Section 280E only applies to businesses dealing in Schedule I or II substances, qualifying medical cannabis businesses may now be eligible to deduct ordinary business expenses such as payroll, rent, and marketing costs. Recreational cannabis operations, however, remain subject to Section 280E restrictions because they continue to be classified as Schedule I.
The lawmakers are seeking specific guidance for businesses that operate both medical and recreational cannabis activities, either under a single license or through separate licenses. They warn that the absence of clear rules could create uncertainty over deductions, tax credits, and compliance obligations.
The IRS has already indicated that guidance is forthcoming and is expected to address expense allocation and transition rules for businesses with both medical and recreational operations. The lawmakers are urging the agency to move quickly and coordinate with other federal agencies, including the Small Business Administration, to ensure the guidance is widely communicated across the industry.
Why it matters: If implemented as expected, the rescheduling change could significantly reduce the federal tax burden for state-licensed medical cannabis businesses by allowing deductions that have long been unavailable under Section 280E, potentially improving profitability and cash flow across the sector.
May 2026: Three Republican-Led States Seek to Block Trump Administration’s Medical Cannabis Rescheduling
Republican Attorneys General from Indiana, Nebraska, and Louisiana have filed a legal challenge seeking to overturn the Trump Administration’s recent decision to reclassify certain medical cannabis products from Schedule I to Schedule III under the Controlled Substances Act. The petition was filed in the U.S. Court of Appeals for the District of Columbia Circuit.
The challenge targets an April 2026 order which moved FDA-approved cannabis products and cannabis sold through qualifying state-licensed medical marijuana programs into the less restrictive Schedule III category. The move does not federally legalize marijuana but reduces regulatory and tax burdens for eligible medical cannabis businesses. The three Republican Attorneys General argue the administration exceeded its legal authority, violated federal administrative procedures, and acted inconsistently with U.S. drug-control obligations under international treaties. They are asking the court to vacate the policy entirely.
The lawsuit highlights divisions within the Republican Party over cannabis policy. While the Trump Administration has pushed forward with medical cannabis rescheduling, several GOP-led states and anti-cannabis advocacy groups are attempting to halt the change. The case comes ahead of broader DEA hearings scheduled for late June and July that will consider whether cannabis should be moved more broadly from Schedule I to Schedule III nationwide.
May 2026: Virginia Governor Vetoes Retail Marijuana Sales Bill, Citing Implementation Gaps in Long-Delayed Framework
Virginia Governor has vetoed a bill that would have created a regulated retail marijuana sales market in the state, extending a long-running policy stalemate over cannabis commercialization. The Governor said the legislation was not ready for implementation, arguing that it lacked sufficient structure, a clear timeline, and the necessary regulatory and enforcement resources to ensure a functioning and responsible marketplace. She also indicated that the proposed framework could create inconsistencies and weaken effective oversight, despite supporting the broader goal of establishing a legal market.
Virginia’s retail cannabis system has effectively been stalled for five years. Although the state legalized marijuana possession in 2021, lawmakers have repeatedly failed to finalize the regulatory structure required to begin legal sales, leaving a “legal but not legal-to-buy” situation in place. The Governor pointed to the unfinished framework as evidence that more time is needed to build a coherent, fully regulated system rather than rushing implementation.
The Governor previously proposed amendments to delay the launch of retail sales and strengthen oversight mechanisms, but these changes were rejected by lawmakers before the bill reached her desk in its original form. As a result of the veto, Virginia’s legal cannabis market will remain in limbo, with retail sales unlikely to begin in the near term unless a new legislative compromise is reached.
May 2026: Georgia Expands Medical Cannabis Program to Broaden Patient Access and Allow Vaping
Georgia has enacted legislation expanding its medical cannabis program, marking a significant shift in how patients can access and use treatment options. The new law broadens the list of qualifying medical conditions, allowing more patients to become eligible for medical cannabis. It also removes previous restrictions that required certain illnesses to be classified as “severe” or “end-stage,” further widening access to treatment.
A key change under the reform is the introduction of vaporization as a permitted method of consumption for eligible patients aged 21 and older. This allows faster-acting delivery compared with oral-only products, which had previously been the primary approved form. The legislation also overhauls dosage rules by replacing percentage-based THC limits with a milligram-based system, effectively allowing stronger and more precisely measured products under regulated caps. Existing “low-THC oil” terminology is being replaced with broader “medical cannabis” language, reflecting the program’s expansion. Overall, the reform positions Georgia’s medical cannabis framework as more flexible and accessible, while maintaining its restriction to non-recreational, physician-approved use.
May 2026: U.S. Cannabis Rescheduling to Schedule III: What It Changes – and What It Doesn’t
The U.S. Department of Justice and Drug Enforcement Administration have issued a final order partially rescheduling cannabis from Schedule I to Schedule III, but the change is narrowly defined and comes with significant limitations. The rescheduling applies only to FDA-approved cannabis-based medicines and cannabis produced and distributed under state-licensed medical programs. This shift formally recognizes medical cannabis within the federal controlled substances framework and is expected to reduce certain regulatory burdens, including easing tax constraints that previously applied under Section 280E. It also establishes a more structured pathway for medical operators to align with federal Schedule III compliance requirements.
However, the order does not legalize cannabis at the federal level, nor does it remove cannabis from the Controlled Substances Act. Recreational or adult-use cannabis remains classified as Schedule I, leaving the broader illicit status of the industry unchanged. Federal and state legal conflicts therefore persist.
The policy also does not resolve key structural issues in the U.S. cannabis market. Banking restrictions, interstate commerce barriers, and the absence of a unified federal regulatory framework remain in place. Adult-use operators receive no immediate benefit from the change, and their tax treatment under existing law is unaffected. A further limitation is that the rescheduling process remains incomplete. A separate administrative hearing process has been initiated to consider broader cannabis rescheduling beyond the medical segment, meaning additional regulatory changes are possible but not guaranteed.
In brief, the reform represents a partial federal recognition of medical cannabis with targeted regulatory relief, while leaving the core federal prohibition framework largely intact.
April 2026: U.S. Reclassifies Cannabis in Partial Policy Shift
The Trump Administration has taken a notable step in U.S. drug policy by reclassifying certain cannabis products under federal law. The move shifts cannabis away from its long-standing placement in the most restrictive category of controlled substances. While the development is historic, its real-world implications are more measured than the headlines suggest.
At the center of the policy change is a revision to how cannabis is treated under the Controlled Substances Act. For decades, cannabis was classified as a Schedule I substance, a category reserved for drugs considered to have a high potential for abuse and no accepted medical use. This placed it alongside substances such as heroin and LSD, and imposed strict limitations on research, prescribing, and commercialization. Under the new approach, the administration has moved FDA-approved cannabis products and certain state-licensed medical cannabis into Schedule III. This category includes substances that are still regulated but recognized as having accepted medical uses and a lower potential for abuse compared to Schedule I drugs. The change was implemented by the U.S. Department of Justice following a broader push to revisit federal cannabis policy.
The implications of this shift are real but targeted. One of the most immediate effects is the easing of restrictions on scientific research. Historically, Schedule I classification made it difficult for researchers to access cannabis for clinical studies. Moving to Schedule III reduces administrative burdens and may facilitate a broader evidence base on medical applications. The reclassification also represents an implicit acknowledgment by the federal government that cannabis has legitimate therapeutic uses. This marks a departure from decades of official policy and brings federal positioning somewhat closer to the reality on the ground, where medical cannabis programs are already established in many states. There may also be limited economic implications. Some cannabis-related businesses – particularly those operating within medical frameworks – could benefit from more favorable tax treatment and potentially improved access to financial services. However, these benefits are likely to be uneven and depend heavily on how the policy is implemented in practice.
Despite these changes, it is important to be clear about what the move does not do. The reclassification does not legalize cannabis at the federal level. Even under Schedule III, cannabis remains a controlled substance subject to federal regulation. Recreational use, while legal in a growing number of states, continues to be illegal under federal law. The policy also does not fundamentally alter the enforcement landscape. It does not automatically lead to the expungement of past convictions, nor does it broadly change criminal penalties associated with unauthorized cannabis activities. Similarly, restrictions on interstate commerce remain in place, meaning cannabis cannot be freely transported across state lines under federal law. In this sense, the United States continues to operate under a fragmented system in which state-level legalization coexists with ongoing federal prohibition. This tension remains one of the defining features of the cannabis market.
The move is therefore best charaterized as incremental rather than transformative. Its scope is limited, focusing primarily on medical cannabis rather than the broader recreational market, which has been a key driver of industry growth. This helps explain why initial optimism in financial markets was tempered as the details became clearer. Additionally, the reclassification does not resolve the structural challenges facing the industry, including restricted access to banking, regulatory uncertainty, and the lack of a unified national framework. These issues would require more comprehensive legislative action to address. There is also a broader signaling element to the decision. By acknowledging medical use and easing certain restrictions, the administration appears to be responding to evolving public attitudes and scientific understanding. At the same time, it stops short of full legalization, reflecting the continued political sensitivity of the issue.
In summary, the Trump Administration’s reclassification of cannabis represents a meaningful policy adjustment, particularly for medical research and regulatory recognition. However, it falls well short of legalization and leaves many of the industry’s core constraints intact. As such, it is more accurately viewed as a symbolic and incremental step within a longer and still uncertain policy evolution.
March 2026: Georgia Moves to Expand Medical Cannabis Program
Lawmakers in Georgia have approved new legislation that would significantly expand the state’s medical cannabis program, with the bill now awaiting the governor’s signature. The legislation, known as Senate Bill 220, would remove the current limit on THC content in medical cannabis products and allow registered patients to use inhalable forms of cannabis such as vaping. Previously, Georgia’s medical marijuana program allowed only low-THC oil products, which limited treatment options and often provided slower relief for patients. Under the new rules, the existing 5% THC cap would be replaced with a system based on total milligrams of THC, giving doctors and patients more flexibility in determining appropriate treatment levels.
The changes are intended to modernize the program and better reflect medical prescribing practices. They represent a major shift for Georgia, which currently has one of the most restrictive medical cannabis programs in the United States, limited mainly to low-THC oil products for certain medical conditions. Meanwhile, recreational cannabis remains illegal in Georgia, although possession of small amounts has been decriminalized in some cities. Overall, the state continues to maintain a strict stance on non-medical cannabis use despite the gradual expansion of the medical program.
March 2026: Texas to Implement Stricter Cannabis and Hemp Regulations with Smokable Hemp Ban
Texas is set to implement major changes to its cannabis and hemp regulations, with the new rules taking effect on March 31, 2026. The new framework significantly tightens the regulation of hemp-derived THC products, particularly targeting smokable products, while allowing certain non-smokable products such as edibles and beverages to remain legal under stricter oversight.
The regulatory changes stem from legislation and regulatory updates approved in 2025, when Texas lawmakers and regulators moved to close what they viewed as a loophole created by earlier hemp legislation. The original hemp law, passed following the 2018 U.S. Farm Bill, allowed hemp products containing less than 0.3% delta-9 THC. However, the law did not account for THCA, a compound that converts into THC when heated. This allowed a large market for smokable hemp flower and high-THC hemp products to develop in Texas. Regulators later moved to change the THC calculation method to “total THC,” which includes THCA, effectively making most smokable hemp products illegal.
Under the new rules effective March 31, 2026, smokable hemp products – including hemp flower and pre-rolls – will be banned from sale and manufacture in Texas. Retailers will be required to remove these products from shelves. However, hemp-derived THC products in non-smokable formats, such as gummies, beverages, and tinctures, will remain legal, provided they meet stricter testing, labeling, and packaging requirements, including child-resistant packaging and verified lab testing.
The new regulations also introduce tighter licensing and compliance requirements for businesses operating in the hemp and cannabis-adjacent sector. Companies will face higher licensing fees, stricter reporting requirements, and more rigorous product testing standards. These changes are expected to increase compliance costs and may lead to consolidation in the industry as smaller operators struggle to meet the new regulatory requirements.
Overall, the new Texas regulations represent a significant shift in the state’s approach to hemp-derived THC products. Rather than full legalization or a complete ban, the state is moving toward a more tightly controlled market, eliminating smokable hemp while allowing regulated non-smokable THC products to remain available.
March 2026: Ohio Tightens Cannabis Market as Hemp THC Ban Takes Effect
Ohio has implemented sweeping changes to its cannabis and hemp markets, introducing stricter limits on licensed marijuana businesses while effectively shutting down the previously unregulated market for intoxicating hemp-derived THC products. At the core of the reform is Senate Bill 56, which caps the number of marijuana dispensaries at 400 statewide and imposes tighter controls on licensing, location, and operations. The law also reinforces regulatory oversight by placing the adult-use market under a centralized authority and allowing local governments to impose restrictions or moratoriums – many of which are already in place across the state.
More significantly, the legislation effectively eliminates the retail sale of intoxicating hemp products – such as delta-8 THC gummies, vapes, and beverages – outside of licensed cannabis dispensaries. As of March 2026, products containing more than 0.4 mg of THC per container can only be sold through the regulated marijuana channel, removing them from convenience stores, smoke shops, and other mainstream retail outlets. This shift aligns Ohio with broader federal changes aimed at closing the so-called “hemp loophole,” which had allowed psychoactive hemp-derived products to proliferate with limited oversight. The new framework effectively forces hemp-derived THC products into the same regulatory regime as marijuana, significantly raising compliance costs and barriers to entry.
The combined impact is a consolidation of Ohio’s US$1 billion annual cannabis market in favor of licensed cannabis operators, while many smaller hemp businesses face potential closure or forced transition into the more tightly regulated system. The law has faced pushback from hemp businesses and advocacy groups, which attempted to launch a citizen-led referendum to block or repeal parts of Senate Bill 56. While the campaign initially gained traction and received approval to collect signatures, organizers ultimately fell short of the required threshold by the March 2026 deadline, meaning the measure will not go to a statewide vote. As a result, the new regulatory framework – including the ban on intoxicating hemp products outside licensed dispensaries – has proceeded without interruption, reinforcing the state’s shift toward a more tightly controlled cannabis market.
Overall, Ohio’s approach represents a decisive pivot toward stricter control and formalization of the cannabis supply chain, prioritizing regulatory oversight and public health concerns over the previously fragmented and loosely regulated hemp-derived THC market.
January 2026: Cannabis Reform at a Crossroads with Federal Momentum and State-Level Friction
The $32-billion cannabis industry closed last year with a rare surge of federal momentum after an executive order directed the Justice Department to accelerate the process of reclassifying marijuana under federal law. The move signaled the most consequential shift in U.S. drug policy since the Controlled Substances Act of 1970. Reclassification would not legalize marijuana at the federal level, but moving it from Schedule I to Schedule III would eliminate punitive tax treatment under Section 280E, delivering billions of dollars in annual relief to licensed operators and materially improving industry profitability.
That optimism is tempered by reality. Marijuana remains classified alongside heroin and LSD while the rescheduling process unfolds, and the timeline remains uncertain. Even if finalized, Schedule III status would still treat cannabis as a controlled substance, leaving federal restrictions on manufacturing, distribution, and possession in place. The existing patchwork of state-regulated markets – medical marijuana legal in 40 states and adult-use sales permitted in 25 states – would continue to exist in tension with federal law.
While cannabis reform edged forward, the hemp sector moved sharply in the opposite direction. Late last year, federal spending legislation included provisions that would effectively shut down the intoxicating hemp market by tightening the definition of lawful hemp-derived products. The change, which targets psychoactive cannabinoids synthesized or concentrated from hemp, places an industry valued at $25–30 billion at risk. Although new legislation has since been introduced to establish a regulatory framework rather than an outright ban, the restrictions are scheduled to take effect in November 2025 unless Congress intervenes.
Beyond federal uncertainty, the marijuana industry faces mounting political resistance at the state level. Organized efforts are underway in several states to repeal existing adult-use cannabis laws, while legal challenges to federal rescheduling are expected if a final rule is issued. Momentum has also slowed markedly: no new state has legalized recreational marijuana since Ohio voters approved adult-use sales in 2023. Together, these factors underscore a reform movement that is no longer advancing in a straight line.
Still, incremental state-level progress remains possible in 2026. In Florida, advocates are preparing another ballot initiative after a prior effort fell short of the state’s 60% approval threshold, though recent polling suggests public support has softened. Hawaii, which legalized medical marijuana through legislation decades ago, continues to struggle to move adult-use legalization through the legislature and may instead turn to voters via a ballot measure. In Pennsylvania, medical marijuana is well established and regional pressure is mounting, as nearly all neighboring states permit adult-use sales, yet legalization efforts remain stalled due to a lack of bipartisan consensus. Virginia presents a different case: adult-use possession is legal, but the state has yet to launch a regulated retail market, leaving the system incomplete despite signals of renewed openness to legislation that would allow sales under stricter regulatory conditions.
Taken together, the cannabis sector enters the coming year at a pivotal moment. Federal policy signals point toward normalization, yet legal, political, and regulatory headwinds persist across both marijuana and hemp. Whether the industry regains momentum or enters a period of retrenchment will depend on how effectively advocates navigate rescheduling, defend existing markets, and rebuild bipartisan support at the state level.
January 2026: Cannabis Legalization Outlook – States to Watch for Recreational and Medical Marijuana Reform
Several U.S. states are positioned to reconsider cannabis legalization in 2026, driven by shifting public opinion, budget pressures, and the potential impact of federal cannabis rescheduling. Both legislative pathways and ballot initiatives are expected to play a central role. On the recreational side, states with existing medical programs and prior near-misses are likely to revisit adult-use legalization, while others may rely on voter initiatives to bypass legislative resistance. Medical cannabis expansion remains a focus in a handful of states that still prohibit cannabis entirely, where patient advocacy and incremental reform have gained traction. At the same time, the outlook is not uniformly expansionary, as some states may also see efforts to restrict or roll back existing cannabis policies, underscoring a dynamic and uneven policy landscape heading into 2026.
Recreational Marijuana Legalization (Likely States)
| State | Likelihood & Context | What to Watch in 2026 |
|---|---|---|
| Florida | Active ballot campaign (Smart & Safe Florida) aiming to place adult-use legalization on the 2026 ballot; legislative attempts also ongoing | Ballot qualification progress, court decisions on ballot language, public polling trends, required 60% vote threshold |
| Hawaii | Growing momentum with governor support and legislative efforts; both legislative and ballot strategies being pursued | Progress of revised bills and potential ballot initiative; legislative committee actions |
| New Hampshire | Multiple legalization bills prefiled for the session; option for constitutional amendment on ballot under consideration | House/Senate votes on legalization proposals; governor’s stance; procedural path to ballot amendment |
| Pennsylvania | Bipartisan legislative efforts with prior House passage; Senate remains a hurdle but rescheduling pressure could shift dynamics | Senate hearings & votes, governor statements, revenue arguments in budget debates |
Nebraska (ballot petition effort) and Wisconsin (legislative proposals and governor interest) could also be possible legalization targets for recreactional marijuana; however, the likelihood is relatively lower for these states.
Medical Cannabis Legalization (Likely States)
| State | Likelihood & Context | What to Watch in 2026 |
|---|---|---|
| Idaho | Certified initiative campaign underway to qualify medical legalization for the ballot; needs tens of thousands of signatures | Signature drive progress; compliance with geographic requirements; potential qualification |
| Kansas | Strong public support and governor’s endorsement of medical reform; past bills passed one chamber but stalled | Legislative committee activity; floor votes in House & Senate; governor statements |
| South Carolina | At least one chamber previously passed medical cannabis legislation; stalled in the other | Reintroduction of bills; floor vote prospects; advocacy pressure |
| North Carolina | Organized council on cannabis regulation and growing executive-level engagement; lays groundwork for possible medical reform | Council recommendations; legislative responses; interim safety/THC regulation proposals |
Some traditionally conservative states (e.g., Alabama) are advancing their medical programs toward implementation but are not “new” legalization states in 2026 – rather, they are completing rollout.
January 2026: New Hampshire Lawmakers Move Forward with Bill to Legalize Adult Cannabis Possession
New Hampshire legislators advanced a Bill in the House that would legalize the possession and use of small amounts of cannabis for adults age 21 and older, marking a renewed push to reform the state’s marijuana laws. House Bill 1235, which cleared initial committee review, would allow adults to legally hold up to 2.5 ounces of cannabis flower, 10 grams of concentrate, and cannabis products with up to 2,000 mg of THC, and permit sharing small amounts without compensation, while maintaining prohibitions on public use and underage possession. Backers argue the measure would reduce low-level drug enforcement and better align New Hampshire with neighboring states, though it does not establish a retail market and still faces uncertain prospects in the full legislature.
January 2026: Decriminalization of Cannabis Possession Under Consideration in Indiana
A legislative change is introduced in Indiana to decriminalize the possession of small amounts of cannabis in the traditionally strict Midwestern state. The proposal would remove criminal penalties for possessing modest quantities of marijuana – such as up to two ounces – turning what is currently a misdemeanor offense into a lesser infraction and reducing jail risk, though it would not legalize sales or establish a regulated market. Backers argue the move would reduce criminal justice burdens and reflect shifting public views, but broader legalization remains politically challenging in Indiana’s legislature.
December 2025: Trump Moves to Reschedule Marijuana, Easing Federal Restrictions
President Trump signed an executive order on December 18, 2025, directing federal agencies to begin the process of reclassifying marijuana from a Schedule I to a Schedule III controlled substance, a significant shift in U.S. drug policy that could reverse decades of strict federal restrictions. Currently classified alongside drugs like heroin and ecstasy with no accepted medical use, marijuana’s potential reclassification to Schedule III would place it in the same category as substances considered to have lower abuse potential and recognized medical uses, such as certain prescription medications. The order aims to expedite medical research, reduce regulatory hurdles, and encourage broader industry participation, though marijuana remains illegal under federal law and its full effect depends on the Drug Enforcement Administration completing a formal rulemaking process.
The announcement sparked optimism within the cannabis industry, as a lower federal classification could unlock billions in research funding, improve access to banking and capital, and potentially reduce business tax burdens, while also drawing mixed political reactions. Some lawmakers and advocates welcomed the move as overdue reform, while critics, including many Republicans, warned it could send the wrong message about drug use. Despite the executive order’s symbolic significance, actual change hinges on regulatory implementation and does not equate to full federal legalization, leaving the landscape of state cannabis laws largely unchanged.
December 2025: Cannabis rescheduling is likely to happen in 2026
President Trump plans to loosen federal restrictions on marijuana use in 2026 despite Conservatives long expressing a degree of discomfort with the idea. Under the plan, Trump will reclassify marijuana as a low abuse potential Schedule III drug; marijuana is currently banned under federal law, classified as a Schedule I drug (i.e. high potential for abuse with no accepted medical use) and faces the same restrictions as more dangerous drugs. A reclassifation would ease restrictions and tax burden while making it easier to transfer the product across state lines and conduct medicinal research. In September 2025, Trump posted a video which advocated for Medicare coverage for hemp-derived cannabidiol (CBD). Public sentiment on marijuana use has been shifting for the past half-century, with Americans increasingly in favor of it. According to Gallup, 64% support legalization, up from 58% in 2015 and 36% in 2005.
April 2025: Cannabis rescheduling left out of White House’s drug policy plan
The White House Office of National Drug Control Policy did not mention marijuana rescheduling or other cannabis reforms in a report detailing the Trump Administration’s top drug policy priorities. This development further strengthens the expectation that neither cannabis rescheduling [from Schedule 1 to Schedule 3] nor a subsequent legalization of cannabis at the federal level is likely to happen during the Trump Administration.
November 2023: Ohio becomes the 24th state to legalize recreational cannabis use
Ohio became the 24th state in the US to legalize recreational (non-medical) cannabis use1. The measure, first introduced in 2022, was stalled by the state’s Republican controlled legislature, triggering a lawsuit to get legalization on the ballot. 57% of the Ohio voters approved the legalization – which will take effect in 30 days.
The new law will allow adults over 21 to purchase and possess up to 2.5oz (70g) of cannabis and to grow up to six marijuana plants at home. Buyers will pay a 10% tax imposed on sales going mostly toward addiction services, communities with cannabis facilities and social equity and jobs programs.
Cannabis is permitted for medical use in 38 US states and it is now legal for adult recreational use in 24 US states, including all west coast states and in Washington DC. More than 50% of Americans live in a state where recreational cannabis is legal. An additional 10 states permit the use of products containing CBD and small amounts of THC. Only two states (Idaho and Nebraska) do not allow for any kind of cannabis use.
October 2023: Georgia becomes the first US state to allow medical marijuana in pharmacies
U.S. Senate will vote on the Secure and Fair Enforcement Regulation (Safer) Banking Act that would allow the federally chartered banks to do business with cannabis companies2. As cannabis is still an illegal controlled substance at the federal level, large financial institutions (banks, insurance companies and payroll services) have been hesitant to serve cannabis businesses.
Meanwhile, Georgia becomes the first US state to allow medical marijuana in pharmacies. Medical marijuana (low THC oil with less than 5% THC) will only available to Georgia residents with approval from a physician to treat severe illness. Patients will be able to buy cannabis oil at pharmacies if they show a state-issued THC registry card and identification.
In the US, 38 states legalized marijuana for medical use and 23 states legalized it for recreational purposes. An additional 8 states decriminalized its use. States with legalized marijuana laws have collected $15Bn in tax revenue between 2014 and 2022 (with $3.8Bn in 2022 alone).
August 2023: U.S. Health Department Recommends Easing Federal Cannabis Restrictions
The U.S. Department of Health and Human Services (HHS) has formally called on the Drug Enforcement Administration (DEA) to loosen federal rules on cannabis, advocating for its reclassification from a Schedule I to a Schedule III controlled substance. Currently categorized under Schedule I alongside drugs such as heroin and LSD – denoting a high potential for abuse and no accepted medical use – the proposed shift to Schedule III would align cannabis with substances like ketamine, anabolic steroids, and codeine formulations. The regulatory downgrade is expected to significantly reduce restrictions on scientific research and ease long-standing financial hurdles.
Following the Health Department’s recommendation, a bipartisan coalition of U.S. senators is moving forward with a cannabis banking bill aimed at resolving the sector’s operational challenges. The proposed legislation would grant federally regulated financial institutions legal protections to provide banking services to state-licensed dispensaries and commercial growers. Financial institutions have historically refused to serve cannabis businesses due to the ongoing federal prohibition, forcing much of the state-legal industry to rely on cash transactions.
July 2023: House Subcommittee Scrutinizes FDA Over Failure to Regulate CBD Products
The U.S. House Subcommittee on Health Care and Financial Services3 has sharply criticized the Food and Drug Administration (FDA) for its ongoing refusal to establish a clear regulatory framework for cannabidiol (CBD) and other hemp-derived products. During a hearing examining federal oversight of the industry, lawmakers highlighted that the agency has continually declined to regulate these consumer items or even formally acknowledge its statutory authority to do so.
Lawmakers argued that the FDA’s regulatory inaction has severely disrupted the marketplace, suppressing the ability of compliant, good-faith manufacturers to safely engage with consumers. At the same time, the absence of federal oversight has allowed bad actors to flood retail channels with potentially unsafe products and unregulated intoxicants. Emphasizing the urgent need for administrative guidelines, committee members stressed that the public requires the FDA to execute its regulatory responsibilities to protect consumers while establishing commercial certainty for farmers, businesses, and the broader hemp sector.
